Aktiesnakken — December 2009
-
nu q&a
-
arzerra i refrac....hvordan er markedet
-
det er analytikernes stinker
-
mellem 80 og 100.000 cll patienter.
-
75% af disse vil være eligble
-
så der vil være 75K patienter US mulige!!!!
-
the market potential is very large under the guidelines!
-
de fleste vil være dækket af medicare
-
safety data gode....
-
fuck hvis det er rigtigt så kan updside være sindssygt
-
de må ikke promote arzerra i andet end labellen, men hun siger at lægerne går efter de guidelines. Så ASH bliver sindssygt afgørende
-
strategien i NHL.....
-
hvornår får vi data fra headtohead
-
unmet medical need
-
ritux behandlede har det ikke godt
-
lav cd20
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind